SCM LIFESCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,030 KRW | +4.12% |
|
+8.41% | -19.84% |
| 2023 | SCM Lifescience Co., Ltd.(KOSDAQ:A298060) dropped from S&P Global BMI Index | CI |
| 2023 | SCM LifeScience to Raise 30.9 Billion Won via Share Issuance | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 586,015 | 233,826 | 175,143 | 77,366 |
| Enterprise Value (EV) 1 | 557,357 | 220,353 | 171,942 | 68,849 |
| P/E ratio | -45.3 x | -8.61 x | -6.35 x | -2.58 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,831 x | 532 x | 442 x | 111 x |
| EV / Revenue | 1,742 x | 502 x | 434 x | 99 x |
| EV / EBITDA | -37.5 x | -20 x | -14.9 x | -5.66 x |
| EV / FCF | -32.5 x | -22.9 x | -22.4 x | -7.91 x |
| FCF Yield | -3.08% | -4.37% | -4.46% | -12.6% |
| Price to Book | 9.29 x | 5.24 x | 7.15 x | 3.78 x |
| Nbr of stocks (in thousands) | 14,250 | 14,426 | 14,545 | 20,467 |
| Reference price 2 | 41,125 | 16,208 | 12,042 | 3,780 |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 320 | 439.3 | 396 | 695.7 |
| EBITDA 1 | -14,858 | -11,020 | -11,538 | -12,158 |
| EBIT 1 | -16,089 | -12,155 | -12,579 | -12,998 |
| Operating Margin | -5,027.71% | -2,767.18% | -3,176.64% | -1,868.29% |
| Earnings before Tax (EBT) 1 | -9,633 | -22,519 | -22,930 | -23,961 |
| Net income 1 | -9,633 | -22,519 | -22,930 | -23,961 |
| Net margin | -3,010.19% | -5,126.47% | -5,790.66% | -3,444.23% |
| EPS 2 | -908.2 | -1,882 | -1,897 | -1,464 |
| Free Cash Flow 1 | -17,164 | -9,620 | -7,677 | -8,706 |
| FCF margin | -5,363.72% | -2,190.04% | -1,938.6% | -1,251.4% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 28,658 | 13,473 | 3,201 | 8,518 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -17,164 | -9,620 | -7,677 | -8,706 |
| ROE (net income / shareholders' equity) | -22.3% | -41.8% | -66.3% | -107% |
| ROA (Net income/ Total Assets) | -17.1% | -11.7% | -18.1% | -27.8% |
| Assets 1 | 56,198 | 193,171 | 126,968 | 86,164 |
| Book Value Per Share 2 | 4,427 | 3,092 | 1,685 | 1,001 |
| Cash Flow per Share 2 | 5.440 | 200.0 | 476.0 | 220.0 |
| Capex 1 | 1,480 | 676 | 505 | 236 |
| Capex / Sales | 462.36% | 153.89% | 127.49% | 33.86% |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -19.84% | 45.83M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- A298060 Stock
- Financials SCM Lifescience Co., Ltd.
